Humacyte (HUMA) to Release Earnings on Friday

Humacyte (NASDAQ:HUMA) is expected to announce its earnings results before the market opens on Friday, March 28th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.

Humacyte Price Performance

NASDAQ:HUMA opened at $3.18 on Friday. The firm has a market capitalization of $400.23 million, a PE ratio of -2.37 and a beta of 1.36. The business’s fifty day moving average price is $3.83 and its 200 day moving average price is $4.63. Humacyte has a 12 month low of $2.75 and a 12 month high of $9.97.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Humacyte in a report on Wednesday, March 12th. Benchmark reaffirmed a “buy” rating on shares of Humacyte in a report on Thursday, February 27th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price objective on shares of Humacyte in a report on Friday, March 7th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Humacyte has an average rating of “Buy” and an average price target of $13.71.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.